You are here » Home » Companies » Company Overview » Glaxosmithkline Pharmaceuticals Ltd

Glaxosmithkline Pharmaceuticals Ltd.

BSE: 500660 Sector: Health care
NSE: GLAXO ISIN Code: INE159A01016
BSE 00:00 | 13 Nov 1604.60 -23.75
(-1.46%)
OPEN

1625.00

HIGH

1630.40

LOW

1592.00

NSE 00:00 | 13 Nov 1604.80 -15.20
(-0.94%)
OPEN

1621.00

HIGH

1634.95

LOW

1591.20

OPEN 1625.00
PREVIOUS CLOSE 1628.35
VOLUME 3597
52-Week high 1699.95
52-Week low 1131.05
P/E 55.03
Mkt Cap.(Rs cr) 27,184
Buy Price 1595.35
Buy Qty 3.00
Sell Price 1601.80
Sell Qty 2.00
OPEN 1625.00
CLOSE 1628.35
VOLUME 3597
52-Week high 1699.95
52-Week low 1131.05
P/E 55.03
Mkt Cap.(Rs cr) 27,184
Buy Price 1595.35
Buy Qty 3.00
Sell Price 1601.80
Sell Qty 2.00

Glaxosmithkline Pharmaceuticals Ltd. (GLAXO) - Chairman Speech

Company chairman speech

With digitisation rapidly remoulding the healthcare landscape we have been at theforefront of leveraging new and emerging technologies in our business.

Dear Shareholders

I am delighted to report that our strategy to put energy where it matters forincreased focus and efficiency to accelerate growth has borne fruit. We have come a longway since we put in place an optimal model for growth. We invested in increasing ourpeople in the frontline equipping them with the capabilities required to excel at thejob. We reduced spend in noncustomer-facing activity. We optimised our product portfolioidentifying key brands behind which we put resources to actively promote. We also have amore structured approach to engaging our trade channel partners with a dedicated team toengage stockists and retailers. This approach has helped us serve our patients and youour shareholders better in 2018-19.

As a science-led company we have always harnessed the power of science and technologyfor achieving better patient outcomes. This year was no different. We recently launchedNucala an advanced biologic therapy for the treatment of severe refractory eosinophilicasthma. India has around 30 million asthma patients - this will bring significant reliefto those among them who have severe eosinophilic asthma. We are committed to bringinginnovative and differentiated medicines from our global pipeline to India as and whenappropriate for meeting unmet and under served healthcare needs. I am proud to share thatour parent company completed the acquisition of Tesaro an oncology- focussedbiopharmaceutical company during the year. Tesaro is on the verge of making significantbreakthroughs in the treatment of advanced endometrial cancer.

With digitisation rapidly remoulding the healthcare landscape we have been at theforefront of leveraging new and emerging technologies in our business. By embracing thepower of Digital

Data & Analytics we are evolving and aspiring to a state of transformationwhereby highly credible scientific data digital tools and experiential learning willsignificantly improve customer engagement and experience.

The breadth of our scientific and technical competencies is amply reflected in ourmanufacturing excellence as well. The plant at Nashik Maharashtra demonstrates bestpractices in manufacturing while continually embedding process improvements. Ourscientific mindset has inspired us to invest upwards of ' 1000 crore in a state-of-the-artgreenfield facility at Vemgal Karnataka. Both the facilities emphasise a safe workingenvironment and production of the highest quality products.

Further with this upcoming facility we are moving towards becoming an unconstrainedsupply chain organisation to serve growing healthcare needs.

Led by our key global priorities of Innovation Performance Trust we will continue tofast-forward to the future with our scientific way of thinking and execution. As animportant pillar of our Trust priority we have made an important commitment to be amodern employer nurturing our employees to be the best version of themselves resultingin highly engaged employees (GSK Culture Survey in April 2019 revealed an engagement scoreof 92%). In alignment with our strategy to put energy where it matters we are committedto enhancing shareholder value by accelerating sustainable profitable growth.

At GSK we believe that it is not just what you achieve that counts but how youachieve it. Our journey over the decades is based on the foundation of our core values andexpectations. We will continue to live our core value of patient focus to realise ourgoal of being one of the world's most innovative best performing and trusted healthcarecompanies.

My deep appreciation to all our shareholders for their continued confidence andsupport.

A. Vaidheesh

Vice President South Asia

Managing Director India